Lab tests shows that Spectricept™ neutralises a variety of common pathogens, including the spores of C. difficile, which are commonly found in hospitals and health care facilities and are a cause of hospital-acquired infection.
Patent-pending formula benefiting from the sporicidal qualities of hypochlorous acid (HOCl) is pH neutral and skin-safe, with a ‘kill time’ of two minutes at concentration levels of 50% and 80%
Lab data indicates that Spectricept™ meets or exceeds both the sporicidal and virucidal standards—EN14476 and EN17126, respectively—to eliminate multiple spores and viruses
London – SpectrumX, a UK-based healthcare and pharmaceutical company, today announces that following successful lab testing, the proprietary, skin-safe formulation of hypochlorous acid (HOCl) contained in the Company’s Spectricept™ product has efficacy in neutralising a wide range of pathogens, including Clostridium difficile spores (C. diff). C. diff spores are often found in health care facilities and hospitals, and the arising bacterium can infect the bowel, causing diarrhoea and other serious health effects. C.diff infections are challenging to treat and often recurrent.
The tests investigated the efficacy of SpectrumX sanitising mist, which is composed of the same patent-pending formulation as the Company’s hand sanitiser, on various bacteria and viruses. In sanitary conditions at a temperature of 20 degrees Celsius, the tests demonstrated that the formulation was effective against C. diff spores, meeting the required test standards with a contact time of two minutes at a 50% concentration level. The formulation met or exceeded both the sporicidal and virucidal standards — EN14476 and EN17126, respectively — to eliminate multiple spores and viruses. (Virucidal refers to a substance or agent that has the capacity to destroy viruses whilst sporicidal refers to a substance or agent that destroys bacterial and mould spores.)
The lab results are a positive development in the wake of a persistent problem throughout the country. Data from Public Health England shows that C. diff infection rates are increasing recently with 12-month rolling case rates showing an increase from 21.9 cases per 100,000 patients in January 2021 to 25.8 cases per 100,000 in the most recent data from June 2022.
Damien Hancox, Chief Executive Officer of SpectrumX, said: “We are delighted that the results of the latest lab data are positive and supporting of our Spectricept™ product containing our proprietary HOCl+ formula, indicating a strong efficacy level against C. diff. spores. The data highlights a low contact time of two minutes to meet or exceed the virucidal and sporicidal standards, enabling us to assist those in hospitals, healthcare facilities and more. This data takes us one step closer to deploying our products across the UK and Europe and enables us to help address critical issues surrounding drug-resistant bacteria.”